Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4047-4056

  Ben Gacem, Riadh ^a   Ben Abdelkrim, Olfa ^a   Ziadi, Sonia ^a   Ben Dhiab, Myriam ^a   Trimeche, Mounir ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Breast cancer; Methylation; MicroRNA

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; MICRORNA; MICRORNA 124A 1; MICRORNA 124A 2; MICRORNA 124A 3; UNCLASSIFIED DRUG; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; MIRN124 MICRORNA, HUMAN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GENE LOCUS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA METHYLATION; AGED; BREAST TUMOR; CANCER STAGING; DISEASE COURSE; DNA METHYLATION; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC;

EID: 84902976439     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1530-4     Document Type: Article

References (35)

1. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427-40. (Pubitemid 34983479)
2. Bestor TH, Verdine GL. DNA methyltransferases. Curr Opin Cell Biol. 1994;6:380-9. (Pubitemid 24170009)
3. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet. 2000;25:338-42. (Pubitemid 30437325)
4. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247-57. (Pubitemid 29519904)
5. Ding WJ, Fang JY, Chen XY, Peng YS. The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer. Dig Dis Sci. 2008;53:2083-9.
6. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce C. MicroRNA expression and function in cancer. Trends Mol Med. 2006;12:580-7. (Pubitemid 44780201)
7. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-5. (Pubitemid 39265675)
8. Esquela-Kerscher A, Slack FJ. OncomiRs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-69.
9. Hammond SM. MicroRNAs as tumor suppressors. Nat Genet. 2007;39:582-3. (Pubitemid 46676097)
10. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BCM Med. 2008;6:14-31.
11. Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M, et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer. 2009;124(10):2367-74.
12. Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, Martin-Subero JI, Cordeu L, Gárate L, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009;69:4443-53.
13. Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010;9:167-81.
14. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 andmiR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31:766-76.
15. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007;67:1424-9. (Pubitemid 46383366)
16. Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R, et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One. 2011;6(4):e19027.
17. Chen X, He D, Dong XD, Dong F, Wang J, Wang L, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54:2248-56.
18. Lv XB, Jiao Y, Qing Y, Hu H, Cui X, Lin T, et al. MiR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. Chin J Cancer. 2011;30(12):821-30.
19. Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, et al. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis. 2013;34(3):713-22.
20. Deng G, Kakar S, Kim YS. MicroRNA-124a and microRNA-34b/c are frequentlymethylated in all histological types of colorectal cancer and polyps, and in the adjacent normal mucosa. Oncol Lett. 2011;2(1):175-80.
21. Elston CW, Ellis IO, Goulging H, Pindre SE. Role of pathology in the prognosis and management of breast cancer. In: Elston CW, Ellis IO, editors. Systemic pathology, vol. 13. 3rd ed. Edinburgh: Churchill Livingstone; 1998. p. 385-433.
22. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-76. (Pubitemid 351413917)
23. Hachana M, Trimeche M, Ziadi S, Amara K, Korbi S. Evidence for a role of the Simian Virus 40 in human breast carcinomas. Breast Cancer Res Treat. 2009;113:43-58.
24. Ben Gacem R, Hachana M, Ziadi S, Amara K, Ksia F, Mokni M, et al. Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients. Cancer Epidemiol. 2012;36:190-7.
25. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-6. (Pubitemid 26296693)
26. Singal R, Ferdinand L, Reis IM, Schlesselman JJ. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep. 2004;12:631-7.
27. Ben Gacem R, Hachana M, Ziadi S, Ben Abdelkarim S, Hidar S, Trimeche M. Clinicopathologic significance of DNA methyltransferase 1, 3a, and 3b overexpression in Tunisian breast cancers. Hum Pathol. 2012;43:1731-8.
28. Choi MS, Shim YH, Hwa JY, Lee SK, Ro JY, Kim JS, et al. Expression of DNA methyltransferases in multistep hepatocarcinogenesis. Hum Pathol. 2003;34:11-7. (Pubitemid 36160016)
29. Grossel MJ, Hinds PW. Beyond the cell cycle: a new role for Cdk6 in differentiation. J Cell Biochem. 2006;97:485-93. (Pubitemid 43265308)
30. Peurala H, Greco D, Heikkinen T, Kaur S, Bartkova J, Jamshidi M, et al. MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. PLoS One. 2011;6:e26122.
31. Zhou X, Marian C, Makambi KH, Kosti O, Kallakury BV, Loffredo CA, et al. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One. 2012;7(6):e39011.
32. Turek-Plewa J, Jagodziński PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett. 2005;10(4):631-47. (Pubitemid 43161688)
33. Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer. 2008;7:15.
34. Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat. 2010;120:581-92.
35. Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y, et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 2013;5:3-13.